1000+ unique media and news posts every 24 hours…
The HC Wainwright analyst has a credit and price gain of US$70.00 for Soleno Therapeutics Inc. (NASDAQ: SLNO) listed. The analysts’ analysis has started looking at DCCR’s results to the new PDUFA date at the end of March 2025. After the analyst’s analysis has started, Soleno Mitte 2025 has started the overall development.
The best Kaufempfehlung and the 12-Monats-Kursziel reflect the following positive representation of the Company on the Soleno-Action more broadly. If optimism increases on Wall Street, analyst prices will lie 67 and 93 US dollars, reaching a strong consensus of 1.38 best.
Part of the financial knowledge of Solenos and the Wachstumspotenzial offer a new Forschungsbericht from InvestingPro, the coverage of the 1,400 US-Aktien ist.
While it is possible that the FDA changed the date of the Prescription Drug User Fee Act (PDUFA) to March 27, 2025, this is the case. The extension that resulted from this, when the FDA got the young Antworten on its Information Fragments as the vital negotiation of the Zulassungsantrags-betrachtet, was also the Prüfzeit-erfordert.
The threatening Extension soll der FDA-ermöglichen, the Prüfung der new data have been removed, or the concerns have a clear insight, Wirksamkeit or Herstellung geäußert wurden.
Soleno reichte de DCCR-Zulassungsantragsprünglich Ended June 2024 ein, woraufhin the FDA in hm the Status one of the previous Prüfung gewährte. This installation was performed on a PDUFA action date for the date of 27.12.2024. Trotz van de Verschiebung van de Zulassungsentscheidung bleibt der Analist probabilistät hännisichtlich von prolongen Aussichten van de Medikamenten und de kleine Auswirkungen van de Verzögerung.
The analysts’ analysis has started looking at DCCR’s results to the new PDUFA date at the end of March 2025. After the analyst’s analysis has started, Soleno Mitte 2025 has started the overall development. The best Kaufempfehlung and the 12-month Kursziel mirror are even more positive if the Firm on the Soleno-Action is wider.
In other active developments, Soleno Therapeutics is in the Fokus der Aufmerksamkeit on the basis of the extension of the FDA guideline for the independence of the DCCR, a treatment for the Prader-Willi Syndrome. The FDA has set a new date for the date of March 27, 2025, but there are no ideas that support the certainty or operation of the device.
Analysts who have rated Baird, Oppenheimer, Laidlaw and Stifel as positive on Soleno will show Baird a price of US$72 and Oppenheimer that the price is based on current developments in the forecast.
Soleno Therapeutics has made a number of moves in the Vorstand vorgenommen, with the experience of Matthew Pauls with a new Lead Independent Director and the appointment of Dawn Carter Bir.
The department that struck a venture with Jefferies LLC has accumulated a huge value of 150 million US dollars seiner stock securities, and has been able to maintain the base of Restricted Stock Units. There are more and more studies that have helped Soleno Therapeutics’ Kurs.
Oppenheimer has a model for the operation of the Soleno and a forecast of a meaningful Wachstum of the US-Sales from 2025 to 2029. The new estimates are based on an erwarteten Anstieg from Diagnose and der planten Preisstrategy for DCCR. The FDA’s divorce over the DCCR until the end of 2024 was a divorced meilenstein for Soleno Therapeutics.
This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.
1000+ unique media and news posts every 24 hours…